Benzinga · Aug 17, 2026
Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
NASDAQ · BVS
Bioventus Inc.
Healthcare · Medical - Devices
$13.45
Down-$0.20 (-1.45%)
Updated Oct 2, 2026, 6:07 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 495.93M
- P/E ratio
- 63.41
- Dividend yield
- 0.00%
- 52-week range
- $6.37 – $15.89
- Volume
- 509.32K
- Avg. volume
- 310.75K
Price performance · BVS
BVS price history
1M range · 0 trading sessions · Daily adjusted prices
BVS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BVS news
The latest Smart Investors Daily articles mentioning BVS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BVS research
Overview
Company profile and research snapshot.
Company profile
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Buy | — |
| Aug 17, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 30, 2026 | Barrington Research | Outperform | — |
| Jun 16, 2026 | Canaccord Genuity | Buy | — |
| May 22, 2026 | Barrington Research | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 17, 2026
Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
SeekingAlpha · Aug 5, 2026
Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Bioventus Inc.
SeekingAlpha · Aug 5, 2026
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q2 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsDavid Crawford - Vice President of Investor Relations &...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
